Innoviva, Inc. Stock price

Equities

INVA

US45781M1018

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
15.24 USD -0.33% Intraday chart for Innoviva, Inc. +1.67% -4.99%
Sales 2024 * 301M Sales 2025 * 334M Capitalization 964M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.83 x
Net Debt 2024 * 187M Net Debt 2025 * 106M EV / Sales 2025 * 3.21 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 112
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.33%
1 week+1.67%
Current month-0.26%
1 month-0.72%
3 months-5.98%
6 months+15.19%
Current year-4.99%
More quotes
1 week
14.97
Extreme 14.97
15.39
1 month
14.48
Extreme 14.48
16.66
Current year
14.48
Extreme 14.48
16.87
1 year
11.11
Extreme 11.11
16.87
3 years
10.64
Extreme 10.64
20.71
5 years
7.58
Extreme 7.58
20.71
10 years
6.36
Extreme 6.36
32.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 20-05-19
Director of Finance/CFO 58 23-08-20
Comptroller/Controller/Auditor 55 14-09-30
Members of the board TitleAgeSince
Director/Board Member 64 18-02-11
Director/Board Member 53 22-12-31
Director/Board Member 73 18-02-11
More insiders
Date Price Change Volume
24-03-28 15.24 -0.33% 490,248
24-03-27 15.29 +2.07% 370,303
24-03-26 14.98 -0.73% 527,022
24-03-25 15.09 0.00% 386,590
24-03-22 15.09 +0.67% 888,906

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
15.24 USD
Average target price
15 USD
Spread / Average Target
-1.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Innoviva, Inc. - Nasdaq